Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians (Q44579110)

4 December 2017

Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians (English)

1 reference

4 December 2017

1

1 reference

4 December 2017

Romney Humphries

2

1 reference

4 December 2017

Daniel Z Uslan

series ordinal

3

1 reference

4 December 2017

David A Pegues

series ordinal

4

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 January 2011

1 reference

Clinical Infectious Diseases

4 December 2017

1 reference

4 December 2017

52

1 reference

4 December 2017

228-234

1 reference

4 December 2017

2

1 reference

Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria

4 December 2017

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Vancomycin-resistant Enterococcus spp.: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Daptomycin resistance in Enterococcus faecalis prosthetic valve endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Infective endocarditis caused by daptomycin-resistant Enterococcus faecalis: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

De novo daptomycin nonsusceptibility in a clinical isolate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against Staphylococcus aureus and Enterococci by FIC index and timed-kill curves

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Daptomycin in vitro activity tested against Gram-positive strains collected from European and Latin American medical centers in 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Daptomycin in vitro susceptibility in European Gram-positive clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

In vitro activity of LY146032 alone and in combination with other antibiotics against gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Effects of combinations of beta-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Control of vancomycin-resistant enterococci in a hospital: a five-year experience in a Taiwanese teaching hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Surveillance studies: how can they help the management of infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Sampling the antibiotic resistome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Baseline Study To Determine In Vitro Activities of Daptomycin against Gram-Positive Pathogens Isolated in the United States in 2000-2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Resistance studies with daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Mechanisms of resistance to daptomycin in Enterococcus faecium

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Multicenter evaluation of the Etest and disk diffusion methods for differentiating daptomycin-susceptible from non-daptomycin-susceptible Staphylococcus aureus isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Calcium-supplemented daptomycin Etest strips for susceptibility testing on Iso-Sensitest agar

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of media

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vi

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial ag

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Control of infections due to extended-spectrum beta-lactamase-producing organisms in hospitals and the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Daptomycin (LY146032) treatment of experimental enterococcal endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Daptomycin-rifampin for a recurrent MRSA joint infection unresponsive to vancomycin-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Efficacy of Daptomycin in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ113

21 January 2018

Identifiers

DOI

10.1093/CID/CIQ113

1 reference

4 December 2017

1 reference